StemCell Therapy

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instabilityhigh metastatic colorectal cancer.

Edward Chu, MD, MMS, director and professor of medicine and molecular pharmacology at Albert Einstein Cancer Center, and vice president for cancer medicine at Montefiore Medicine, discusses the role of pembrolizumab (Keytruda) in patients with mismatch repair deficient (dMMR) or microsatellite instabilityhigh (MSI-H) metastatic colorectal cancer (mCRC).

The phase 3 MK-3475-177/KEYNOTE-177 trial demonstrated a significantly improved overall response rate, duration of response, and progression-free survival with pembrolizumab versus investigators choice of standard-of-care chemotherapy, says Chu. Moreover, pembrolizumab demonstrated a favorable safety profile compared with chemotherapy.

On June 29, 2020, the FDA approved pembrolizumab as a first-line therapy for patients with unresectable dMMR or MSI-H mCRC based on results from the KEYNOTE-177 study. The regimen should now be considered a standard of care for this patient population, Chu adds.

Notably, patients with dMMR or MSI-H mCRC account for about 5% of the overall mCRC population.Although the subset is small, the activity of pembrolizumab in this space confirms the need for precision medicine and personalized therapeutic approaches for patients with CRC, concludes Chu.

Here is the original post:
Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC - OncLive

This entry was posted on October 2, 2020 at 10:59 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |